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 ABSTRACT 
 
In the course of the development of the first adenosine A3 receptor PET tracer 
[18F]FE@SUPPY, SUPPY:0 (4,6-diethyl-2-phenyl-5-(sulfanylcarbonyl)pyridine-3-
carboxylic acid) (4) was reported as versatile synthesis precursor for SUPPY-type 
radiotracers. Thus, the aim of this thesis was the preparation of several SUPPY:0 derivatives, 
which were required as precursors for radiolabeling and as reference compounds for HPLC 
analysis. With few exceptions microwave-assisted synthesis was used to prepare each target 
compound in one to two steps starting from compound (4). SUPPY:0 was alkylated with 
different alkyl halides and alkyl triflates under yielding in most cases O/S - regioselective 
products. 
In conclusion, one new compound (6) has been developed and nine new synthetic pathways 
for derivatives already known (1-3, 5, 7) were established. 
 
 
 
  
 
 EXPOSÉ 
 
Im Rahmen der Entwicklung des ersten Adenosin-A3-Rezeptor-PET-Tracers, 
[18F]FE@SUPPY wurde SUPPY:0 (4,6-Diethyl-2-phenyl-5-(sulfanylcarbonyl)pyridin-3-
carbonsäure) (4) als ein vielseitiger Syntheseprecursor für Radiotracer dieser Art beschrieben. 
Das Ziel der vorliegenden Arbeit war daher die Herstellung mehrere SUPPY:0 Derivate, 
welche als Precuror für Radiosynthesen und als Referenzsubstanzen für HPLC-Analysen 
dienen sollen. Mit einigen Ausnahmen wurden die Zielverbindungen durch 
mikrowellensynthesen-assistierte organische Synthese in einem oder zwei Schritten 
hergestellt. Die für alle Mikrowellenversuche verwendete Ausgangsverbindung, SUPPY:0 (4) 
wurde mit verschiedenen Alkylhalogeniden und Alkyltriflaten unter Mikrowellenbedingungen 
alkyliert, wobei in den meisten Fällen O/S-regioselektive Produkte entstanden. 
Im Rahmen dieser Arbeit wurde eine neue Verbindung (6) hergestellt und außerdem neun 
neue Synthesewege für bereits bekannte Verbindungen (1-3, 5, 7) erschlossen. 
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 1 
1 INTRODUCTION 
 
1.1 Adenosine and adenosine receptors 
 
1.1.1 Adenosine 
 
As a nucleoside, adenosine (fig. 1) is an important molecule for biochemical processes as well 
as for signal transduction. It is formed by the purine base adenine which is attached to the 
monosaccharide β-D-ribose by a β-N9 - glycosidic bond.1,2 
 
 
Figure 1:
3
 Adenosine 
 
Adenosine is released from metabolically stressed or active cells and binds specifically to A1, 
A2 and A3 cell surface receptors, and acts as a regulatory molecule.
4
 
It is omnipresent in body fluids and plays an important role in the energy transfer in all cells 
in form of adenosine triphosphate (ATP). Furthermore, adenosine has enormous effects on the 
cardiovascular as well as the neurological system, the gastrointestinal tract, and the immune 
system. By inhibiting the release of excitatory neurotransmitters like acetylcholine, dopamine 
and noradrenalin, adenosine causes vasodilatation and thereby reduces blood pressure.
5
  
In spite of this fact, adenosine is not used clinically as a vasodilator, due to its short acting. In 
human blood, its half-life is only ten seconds. In addition, it can cause coronary vascular steal 
syndrome.
6
 However, adenosine is used as an antiarrhythmic drug for the rapid treatment of 
supraventricular tachycardia.
6,7
 
 2 
In principle, there are two metabolic pathways for adenosine in the human body. The first one 
is its degradation. Adenosine is metabolized in red blood cells by adenosine kinase and also, 
but to a smaller degree, by adenosine deaminase to adenosine monophosphate (AMP) and 
inosine, which again is catabolized to hypoxanthine, xanthine, and eventually to uric acid (fig. 
2).
8
 Its second pathway is the chemical recovery, where the nucleoside can be 
rephosphorylated to AMP by the adenosine kinase.
6
  
 
 
Figure 2:
9
 Adenosine metabolism 
 
Adenosine is also part of energy rich compounds such as nucleic acids (DNA, RNA), 
adenosine triphosphate (ATP), adenosine diphosphate (ADP), and adenosine monophosphate 
(AMP).
10
 As mentioned above the triphosphate unit, ATP is needed for the cellular energy 
transfer. The stored energy of the two reactive phosphoanhydride bonds is released by 
hydrolysation and so available for cellular processes or chemical reactions. Thereby ATP is 
transformed to ADP.
11
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1.1.2 Adenosine receptors  
 
The three different adenosine receptor subtypes are called A1, A2 and A3 adenosine receptors 
according to the International Union of Pharmacology (NC-IUPHAR).
12
 These receptor 
subtypes are G-protein-coupled receptors, consisting of seven transmembrane domains with 
common signal transduction pathways.
13
 The receptors either lead to inhibition (A1 and A3) or 
to stimulation (A2) of the enzyme adenylate cyclase
14
 and differ in their pharmacological 
profile as well as in the tissue distribution (fig.3).
2
 
 
 
Figure 3:
14
 Distribution of adenosine receptors in the human body 
 
1.1.2.1 The adenosine A1 receptor 
 
High expression rates of A1 receptors in the human body were found in the brain, heart, 
stomach, kidneys, liver, immune system and in blood vessels amongst others. Agonists cause 
negative inotropic and chronotropic effects.
15, 16
  
 4 
Pharmacological data show that the A1 receptor is important for activating the mitochondrial 
ATP-depending K
+
-channels, which results in protection of the heart from ischemia-
reperfusion injury.
12
 Furthermore, A1 receptors have neuroprotective effects on the brain. By 
stimulation of this receptor subtype, the release of glutamate is inhibited causing a decrease of 
excitatory effects.
17
  
 
1.1.2.2 The adenosine A2 receptor 
 
This receptor subtype can be classified into the adenosine A2A receptor and the adenosine A2B 
receptor. 
The A2A receptor is expressed in a few regions of the human brain such as the striatum and 
the nucleus accumbens. It plays a pivotal role in neurodegeneration and migraine and could be 
involved in Parkinson’s and Huntington’s disease.15 Furthermore, the activation of A2A 
receptor in blood vessels causes vasodilatation and consequently decreases blood pressure.
16,18
 
This receptor type also occurs on immune cells, including monocytes, lymphocytes and 
macrophages. Thus, the activation of this receptor depending on adenosine involves anti-
inflammatory effects,
19-21
 which can terminate chronic inflammatory processes. 
The A2B receptor is widespread on almost every cell type.
22
 The stimulation results in the 
degranulation of human mast cells and causes bronchoconstrictory effects.
23-25
 Additionally, 
the A2B receptor is located on cells of the intestinal tract where it is involved in the regulation 
of chloride channels.
26
  
 
1.1.2.3 The adenosine A3 receptor 
 
The A3 receptor subtypes were not only detected in high concentrations in human lung and 
liver cells, but also in the heart, kidneys, brain and spleen.
15 
In rats adenosine A3 receptor 
mRNA was located in testes, heart and brain.
27
 However, the A3 receptor subtype has been 
found to be involved in a variety of diseases, such as epilepsy,
28
 stroke,
29
 cardiac,
30
 and 
cerebral ischemia.
31
 Furthermore, the receptors play an important role in the cell cycle.
32
 
Activation of A3 adenosine receptors lead to deceleration of the cell cycle
33
 as well as to 
changes in the cytoskeleton.
34
 Studies have shown that A3 receptors are expressed on the cell 
 5 
surface of many tumor cell lines and could therefore serve as target for tumor imaging and 
inhibition of tumor growth.
35
 
In recent years, many compounds were identified as potential A3 receptor antagonists such as 
flavonoids, xanthenes, thiazol pyridines and 6-phenyl-pyridines.
36
 Li et al
37
 evaluated a series 
of molecules, investigating their affinity and selectivity towards the adenosine A3 receptor. 
Among these compounds, the fluoroethylester (2-fluoroethyl-4,6-diethyl-5-
[(ethylsulfanyl)carbonyl]-2-phenylpyridine-3-carboxylate, fig. 4) exhibited promising results 
regarding the affinity and the selectivity towards A3 receptors.
2
 
 
 
Figure 4: 2-Fluorethyl 4,6-diethyl-5-[(ethylsulfanyl)carbonyl]-2-phenylpyridine-3-carboxylate 
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1.2 Radioactivity 
 
The term “radioactivity” was first coined by Marie Curie, who discovered the spontaneous 
disintegration of elements into smaller pieces.
38
 Several atomic nuclei, also called parent 
nuclides, have the ability to emit ionizing particles or gamma radiation by releasing energy 
and turning into stable chemical elements, the daughter nuclides. These stable chemical 
molecules have less energy content than the parent nuclides.
39
  
In general, radioactivity can be divided into two types:
40
 
1) natural or spontaneous radioactivity, defined as spontaneous disintegration of an 
unstable atomic nucleus and the emission of particles or electromagnetic radiation 
and  
2) artificial or induced radioactivity which is produced by bombarding naturally 
occurring isotopes with subatomic particles or with high levels of x-rays or gamma 
rays.  
Radiation can be measured by decay rate, also called activity, which is defined as the number 
of transforming atomic nuclei of a radioactive nuclide during a certain period of time. The SI 
unit for radioactivity is Becquerel (Bq) according to the General Conference on Weights and 
Measures (CGPM). It is defined as one decay per second.
41 
 
1.2.1 Forms of decay 
 
Radioactive nuclei decay in different modes depending on their composition concerning 
protons and neutrons. Important modes of decay are alpha decay, where two protons and two 
neutrons are emitted as a helium nucleus and beta decay, differentiating beta plus and beta 
minus decay. In this mode of decay an electron or positron, also called beta particle, is 
emitted. The third mode of decay is gamma decay, which is a form of high frequent 
electromagnetic radiation.
39,
 
42
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1.2.1.1 Alpha decay 
 
Alpha decay, a corpuscular form of radiation, preferentially occurs in nuclei with a high mass 
number. During the decay, an alpha particle consisting of two neutrons and two protons (fig. 
5), is emitted with high energy from the mother nuclide with almost 10% of speed of light.
39
 
 
 
Figure 5:
43
 Alpha particle consisting of two neutrons and two protons
 
 
Generally speaking, a nucleus (X) converts into a new atom (Y) and a 
4
He nucleus, the alpha 
particle. The newly formed atom exhibits a mass number A minus 4 and an atomic number Z 
minus 2 (fig. 6).
40
  
 
  
Figure 6
44 
 
Alpha particles possess a huge amount of binding energy, which promotes spontaneous alpha 
decay.
41
 The typical kinetic energy varies between 2 and 5 MeV. However, numbers can rise 
even to 10 MeV, when creating such particles artificially.  
Uranium, radium and thorium, so called heavy elements, undergo alpha decay, because of 
their energy rich structure. Nevertheless, also light elements have the ability to emit alpha 
rays like nuclides of tellurium, with mass numbers 100 to 106. As mentioned above, alpha 
particles exhibit high mass and low velocity, due to interaction with the surrounding matter, 
which causes only low depth of penetration. Depending on their energy, the mean free path of 
alpha particles under normal conditions amounts to 10 cm. Thus, a decrease of air pressure, 
and therefore fewer collision partners results in an increase of the mean free path. Thus, alpha 
radiation can easily be shielded by a sheet of paper or by creating a rather short distance to the 
source of radiation. 
 8 
Alpha rays are relatively harmless to the human body if exposure occurs externally because of 
their inability to penetrate the skin. Nevertheless, the intake through inhalation, wounds, 
mucosa or even oral intake is considered dangerous and can cause serious damage to living 
cells. Due to the long half life and strong ionizing effects of alpha radiation, it is not used for 
diagnostic purposes.
41, 42
 
 
1.2.1.2 Beta decay
41, 42
 
 
Beta decay can be divided into beta plus (β+) and beta minus (β-)-decay.  
Beta minus radiation is a corpuscular radiation consisting of electrons. Especially nuclides 
with high amounts of neutrons undergo this type of decay.  
 
 
Figure 7:
43
 Beta minus particle  
 
During this mode of decay, an electron (e
-) as well as an electron antineutrino (νe), together 
called beta minus particles, are emitted, while conversion of a neutron into a proton occurs, 
which results in the transformation of the mother nuclide into a daughter nuclide (Y), with the 
mass number A and atomic number Z plus 1 (fig. 8). 
 
 
Figure 8
44
 
 
Beta plus radiation, which provides the basis for positron emission tomography, also belongs 
to corpuscular radiation. During this decay, a nuclide high in protons transforms a proton into 
a stable neutron, while emitting a positron (e
+) and an electron neutrino (νe). Thereby, the 
decay energy is distributed equally as kinetic energy between both, the neutrino and positron. 
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The newly formed atom (Y) shows an unchanged mass number A but an atomic number Z 
minus 1 (fig. 9). 
 
 
Figure 9
44
 
 
As antimatter positrons possess the characteristic of being instable when in contact with 
matter, which results in annihilation. Thereby, a positron colliding with an electron causes the 
conversion of their mass-energy into electromagnetic radiation. Annihilation radiation is 
emitted as two gamma quanta in an angle of 180 degrees with an energy of 511 keV, which is 
exploited in positron emission tomography (PET) (fig. 10). 
 
 
Figure 10:
45
 Annihilation and detection via PET 
 
Beta rays interact with matter to a lesser extent than alpha rays. For this reason beta radiation 
exhibits a longer mean free path than alpha radiation. Exposed to the human body, this type of 
radiation can damage several skin layers resulting in radiation burns and can cause long-term 
consequences, such as skin cancer. In case of intake, this ionizing radiation severely affects 
the surrounding tissue by causing mutation of cells However, beta radiation is exploited 
therapeutically for several diseases, such as colon cancer, hepatic cancer
 
and bone cancer.
46-48
 
 10 
Another field of application is medical imaging with positron emission tomography (PET), 
which uses beta plus emitter labeled molecules as tracer molecules. 
Lower-atomic-number materials are commonly used to shield beta rays, such as aluminum or 
plastic materials. 
 
1.2.1.3 Gamma decay
41, 42, 49
 
 
Gamma radiation is a form of electromagnetic radiation of high frequency. In contrast to 
alpha and beta rays, gamma rays have a large depth of penetration and are referred to as 
indirectly ionizing radiation since having no charge, they mostly pass through matter until 
they interact with a particle. When such collision occurs, gamma radiation transfers energy to 
the particle, such as an electron. The excited electron can then directly interact with other 
electrons or atoms and cause ionization, which is why the process is called indirect ionization. 
Gamma radiation needs to be shielded appropriately with higher-atomic-number materials of 
high density such as lead and concrete. 
Gamma decay occurs in natural and artificially produced radioactive isotopes. In case of a 
nuclear transformation through alpha or beta decay, the daughter nuclide remains in an 
excited state. Even though further emission of particles is not possible, excess energy of the 
nucleus is transformed into electromagnetic radiation and emitted as gamma quanta with the 
speed of light (fig. 11).  
 
 
Figure 11:
43
 Gamma quanta 
 
Mass number A as well as the atomic number Z of a nuclide do not change as a result of 
gamma decay. It merely results in the loss of binding energy of the nucleus (fig. 12). This 
energy of gamma quanta varies between 0.1 and 20 MeV.  
 11 
 
Figure 12
44
 
 
1.2.2 Background radiation 
 
Natural radiation reaches the earth from everywhere and living organisms are persistently 
exposed. When life on earth began about 3.5 billion years ago, the natural level of radiation 
was approximately three to five times higher than today.
50
 It could be possible that the high 
radiation was needed in former times to initiate life and it still could be needed to sustain 
these species, as studies with bacteria and protozoa have shown.
51
 
Background radiation can be divided into cosmic and terrestrial radiation. Cosmic radiation 
increases with magnetic latitude and altitude and bombards the earth continually with high-
energy particles, originating in outer space. Interacting with the nuclei of atmospheric 
constituents, these rays produce secondary reaction products and a cascade of interactions, 
known as radioactive nuclei like 
3
H and 
14
C.
52
 
Terrestrial radiation can be classified as external and internal radiation. As for external 
radiation there is radioactive content in soil, building material or the environment.
53
 This kind 
of radiation, originates from common elements like carbon (
14
C), potassium (
40
K), uranium 
(
238
U) and thorium (
232
Th) or their decay products radium and radon, which have existed since 
the beginning of the earth. Internal exposure arises from the intake of terrestrial radionuclides 
by ingestion or inhalation.
52
  
The individual ratio of natural radiation for human beings is about 2.2 mSv per year. This 
amount varies from location to location on earth. In some regions, such as Brazil, India or 
Iran, the natural dose rate is much higher than in other parts of the world. Nevertheless, 
people, animals or plants living there have never shown malign effects despite this high 
radiation.
54
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1.2.3 Artificial radiation 
 
Artificial radiation emanates exclusively from man-made production. Its principles are the 
very same as of natural radiation. By bombardment of atomic nuclei with either alpha or 
gamma rays as well as neutrons, protons or other atomic nuclei, such radionuclides can be 
produced. Due to their short half-life, they have to be created in-situ for each application 
purpose. Only long-lived radionuclides or stable nuclides can be used as parent nuclides.
41
  
In 1919, the first artificial nuclear transformation was accomplished by E. Rutherford.
55
 Irène 
Joliot-Curie, daughter of Marie Curie, first coined the term “artificial radiation” in the place. 
Together with her husband, Frederic Joliot-Curie she discovered artificial radioactivity and 
was therefore awarded the Nobel Prize in 1935.
56
  
In general, there are three different ways of producing radioactive nuclides:
41
 
- Neutron-rich radionuclides are produced by nuclear fission or by neutron irradiation of 
the parent nuclide in a nuclear reactor, whereas  
- neutron-poor radionuclides are produced by using a generator or cyclotron.  
 
1.2.3.1 Radionuclide production by nuclear reactor 
 
Nuclear fission, also just called fission,
57
 is defined as a process in which highly excited and 
instable nuclides of high atomic mass decay into several fragments, showing medium atomic 
mass while releasing energy.
41
  
Before producing radionuclides in nuclear reactors, nuclear fission (spontaneous fission) was 
detected in uranium by Flerov and Petrzhak.
58
 
Nuclear fission is usually carried out in a nuclear reactor. It can be divided into distinct stages. 
The first stage consists of a division of the excited, original nucleus through a neutron flux 
with no loss of energy or particles. These primary fission fragments emit energy in form of 
photons, neutrons and sometimes alpha particles. The final process in nuclear fission is the 
beta decay, accompanied by photon emission which results in stable nuclei (fig. 13).
59
  
 
 13 
 
Figure 13:
60
 Nuclear fission (modified) 
 
Such nuclei are 
3
H (t1/2 = 12.3 a), 
14
C (t1/2 = 5730 a), 
33
P (t1/2 = 25.3 d), 
35
S (t1/2 = 87.5 d), and 
125
I (t1/2 = 59.4 d). They are mostly used for scientific and medical purposes.
41
 
 
1.2.3.2 Radionuclide production by radionuclide generator 
 
In general, this system consists of a column containing absorbent material, such as aluminum, 
an inlet and an outlet. It is shielded against radioactive radiation by lead (fig. 14).  
 
 
Figure 14:
61
 Radionuclide generator (modified) 
 
Long-lived parent nuclides, such as 
99
Mo, can be absorbed onto the supporting material. The 
decay of the nuclide results in the formation of the daughter nuclide. In case of 
99
Mo, 
99m
Tc is 
 14 
formed, which can be obtained from the generator column by eluting with a washing 
solution.
62
 Especially 
99m
Tc is a commonly used nuclide since its application possibilities in 
single photon emission computed tomography (SPECT) are widespread.
55
  
 
1.2.3.3 Radionuclide production by cyclotron 
 
In 1929, E. Lawrence concluded that raising the energy of ions in small steps using low 
voltages would be the simplest way of accelerating ions to high enough energies to induce 
nuclear reactions. He was the first one, who elaborated a concept for a cyclotron by using a 
magnetic field to bend the ion’s paths into circular arcs. Thereby, they could be repeatedly 
accelerated by the same electrodes as well as excited by an alternating voltage resulting in an 
energy gain at each gap crossing. Based on these facts, four different accelerator types have 
been developed (chronological order):
63
 
 
- Synchrocyclotrons with energy rates of 1 GeV allowing artificial production of pions 
and muons. 
- Synchrotrons, where a magnetic field is added. 
- Isochronous cyclotrons, where the magnet is split into several sectors to create extra 
focusing forces. 
- Fixed-field alternating-gradient (FFAG) accelerators with split magnets and 
modulated frequency. 
 
Today’s cyclotrons mainly consist of an electromagnet around a flat vacuum chamber 
between two dipoles. They can produce high-energy ion beams without the problems 
associated with high voltages, resulting in artificially produced isotopes (fig. 15). This 
concept is based on the early experiments of N. Edlefsen and his follower M. Stanley 
Livingston, both graduate students of E. Lawrence.
63
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Figure 15:
64,65
 Cyclotron at its beginnings (left), cyclotron today, cross section (right) 
 
New isotopes were formed and soon used in studies of biological and chemical processes. 
Also medicine profited from the discovery of these isotopes, such as 
14
C, 
24
Na, 
32
P, 
59
Fe and 
131
I. Especially 
32
P was proven beneficial for diseases like leukemia and polycythemia.
63
  
Today, cyclotron-produced beta minus emitters, 
67
Cu (t1/2 = 2.6 d) and 
186
Re (t1/2 = 3.7 d), are 
used for radiosyntheses of tumor affine substances, while alpha emitter, 
211
At (t1/2 = 7.2 h) and 
255
Ac (t1/2 = 10.0 d), mainly find their use in the treatment of thyroid carcinoma.
55
 
 
1.3 Nuclear medicine and radiopharmaceuticals 
 
Since radioactivity was first discovered at the end of the 19
th
 century, the history of nuclear 
medicine has been rather short. In the 1940s, the first nuclear medical examinations of the 
thyroid were carried out, and it was not until 1985 that the first clinical application of a 
positron emitting nuclide was described.
66
 When significant improvement in the 
instrumentation was made, positron emission tomography (PET) became important as a 
diagnostic tool. Investigating potential radiotracers for PET, Ido et al
67
 developed [
18
F]2-
fluoro-2-deoxy-D-glucose, which in fact was the first established radionuclide. Hamacher and 
Coenen improved the synthesis of this compound, which led to continued success of 
[
18
F]FDG.
68
 In the following years, further studies concerning PET and PET-tracers were 
performed in order to develop more selective and specific tracers. Thus, more information and 
better knowledge about neurological, cardiological and oncological diseases can be obtained 
today.
69 
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1.4 Positron emission tomography (PET) 
 
Positron emission tomography, is finding its use in nuclear medicine and is an important non-
invasive, scientific and clinical tool for probing biochemical processes in the human body. 
This powerful imaging technique is mainly used for quantitative measurement such as 
metabolic levels and biological processes in vivo.
70
 Due to its sensitivity and versatility, it has 
become an important tool in clinical research as well as in routine diagnostics.  
In general, PET consists of two merged techniques, both awarded with the Nobel Prize. The 
first one is the tracer principle, which was invented by de Hevesy in 1943, and the second 
technique is the tomographic principle, devised by Houndsfield and Cormack in 1979.
71
  
 
1.4.1 Tracer principle 
 
Radionuclides used for PET are pure positron emitters and mostly short-lived. Such nuclides 
are 
11
C (t1/2 = 20 min), 
18
F (t1/2 = 110 min), 
13
N (t1/2 = 10 min) and 
15
O (t1/2 = 2 min). The 
advantage of the nuclides above is that they can be introduced directly into biomolecules. 
Time is a critical parameter in the production of radiotracers. These short-lived radioisotopes 
need to be produced and used for imaging within a time compatible with the half-life of the 
PET nuclides.
70
 However, also long-lived nuclides, such as 
129
I, are getting more popular for 
the use in PET due to the resulting extension of the physiological time window of PET.
71
 
Producing radiotracers for PET requires at the preparation of appropriate nuclides, which are 
produced in a cyclotron. This method affords the labeling nuclide in an unreactive form, 
which has to be chemically activated (e. g. reduction of 
11
CO2 to methyl iodide).
2, 70
 
A variety of synthetic methods and techniques are available for the labeling of biomolecules 
with a positron emitter, such as standard procedures of labeling carboxylic acids with 
[
18
F]bromofluoroethan.
72, 73
 Fast and effective PET radiochemistry is necessary for the 
production of specifically positron-emitter-labeled tracer molecules with high specific 
activity. On the one hand, the timeframe, as explained above, plays a crucial role, that is why 
the synthesis of a radiotracer should be accomplished within three half lives. On the other 
hand, the use of very small amounts of reactants in radiosynthesis significantly increases 
radiochemical yields.
74
 
 17 
For a PET scan only nanomolar amounts of a radiotracer are required to be injected in the 
human body averting any pharmacological effects of the radiotracer. Kinetic modeling and 
mathematical characterization of the data acquired in a PET scan allows the measurement of 
several parameters like enzyme activity, biosynthesis rate and receptor density. An important 
prerequisite for optimal binding of radioligands to their targets is the fast penetration of the 
blood-brain barrier. Furthermore, polar properties of the tracer are required for a fast 
clearance from the brain.
74
 
 
1.4.2 Tomographic principle 
 
When emitted positrons lose kinetic energy through collision with electrons in surrounding 
tissue, so called short-lived positroniums are created. By annihilation, their mass is converted 
into energy, which is emitted in form of two 511 keV gamma photons in an angle of 180 
degrees.
75
 The annihilation radiation can be detected with coincidence detection, a rather 
novel technique in nuclear medicine.
76
 Thereby, scintillation detectors, containing bismuth 
germanate (BGO) or lutetium oxyorthosilicate (LSO) crystals, and photomultiplier tubes, are 
placed opposite to the source of positron emitters. By measuring a coincidence event the 
location of the annihilation event can be calculated along a line joining these two detectors 
(called line of response or LOR). 
 
 
Figure 16:
77
 Positron emission tomography - data evaluation 
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Each pair of parallel and opposite detectors is able to produce a coincidence line. Thus the 
position of an annihilation event can be localized. This line is unique in terms of location and 
direction. Many coincidence lines form a data set also called sinogram. These data however 
need to be corrected for tissue alternations and detector non-uniformity. Thereafter, the 
sinogram data can be used to reconstruct the image by the use of iterative technique or filtered 
back projection (fig. 16). Today a patient, subjected to a PET-scan, is surrounded by hundreds 
of detectors in form of a ring. Coincidence events are detected and yield information about the 
concentration and distribution of the positron emitter within the patient.
75
  
 
1.4.3 2-[
18
F]-fluoro-2-deoxy-D-glucose 
 
2-[
18
F]-fluoro-2-deoxy-D-glucose (fig. 17) is not only a widespread PET tracer, but also one 
of the earliest PET tracer molecules.
66
 It is a D-glucose analog and is converted in cells into 
[
18
F]FDG-6-phosphate ([
18
F]FDG-6-PO4) by the enzyme hexokinase. 
 
 
Figure 17:
78
 Fluorine-18 labeled D-glucose 
 
By being metabolically trapped, [
18
F]FDG-6-PO4 accumulates in tissues, since [
18
F]FDG is 
lacking the 2’-hydroxyl group further metabolization is not possible. Its accumulation rate is 
proportional to the phosphorylation rate of exogenous glucose as well as the D-glucose 
utilization of the tissue. [
18
F]FDG accumulates mainly in the brain and the heart of the human 
body, because these tissues have a high glucose turnover rate Due to increased glycolysis 
[
18
F]FDG also accumulates in malign tissue. With its half life of only 110 min, fluorine-18 
labeled D-glucose is especially useful in positron emission tomography, due to the short 
exposure to radiation of the human body.
79
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1.4.4 Development of new PET radiotracers 
 
For the development of new PET pharmaceuticals several aspects must be, considered:
80
 
 
- choice of labeling position in the tracer molecule 
- stereochemical properties 
- choice of the cyclotron produced primary precursors and online production of the 
secondary precursors 
- chemical properties concerning mode of the precursor molecule and choice of solvent 
- choice of solvent for final formulation 
- expected clinical result for the nuclear medicinal outcome 
 
Synthesis of all radiotracers in PET first starts with small cyclotron-produced precursors. The 
number of chemical modes of the commonly used tracer nuclides (
11
C, 
18
F, 
13
N and 
15
O) is 
limited due to extreme conditions in the cyclotron. By the end of a radiation process, stable 
and rather unreactive molecules are formed, which is related to thermodynamic determination 
of the chemical mode through high energy. 
11
C and 
18
F as well as 
13
N and 
15
O can be 
developed by bombardment with protons, deuterons, 
3
H or 
4
H causing a multitude of nuclear 
reactions. Nevertheless, just one or two of the above reactions are applied to every isotope. 
Mostly, protons are used as projectiles because of their effortless availability and their low 
price.
70
 
Another important characteristic of radiotracers is their specific activity, meaning the ratio of 
radiolabeled molecules to the total number of molecules. The major aim of PET is the 
analysis of physiological processes without interference. Thus, the lower the amount of 
radiotracers relative to native molecules caused by high specific activity, the less interference 
and disturbance of analyzed processes. In measuring receptor density and enzyme 
concentration, this knowledge is of great significance.
81
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1.4.5 Application field of PET 
 
Positron emission tomography is mainly used in the neurological and cardiological field. 
Neurological diseases like Morbus Alzheimer, Parkinson, epilepsy or Chorea Huntington can 
be diagnosed and analyzed. In cardiology, PET is useful for studying atherosclerosis and 
related vascular diseases.
82
 
Today, about 70% of clinical PET use affects oncologic diseases.
83
 Due to high glycolytic 
rate, [
18
F] FDG-6-PO4 is trapped in cancer cells and can be monitored easily via positron 
emission tomography. Lymphoma, melanoma and breast cancer are just a few forms of 
cancer, which can be detected. By measuring the metabolic activity a differentiation between 
malignant and normal tissue can be made.
82
 
Furthermore, monitoring the response to treatment and establishing prognostic information 
are advantages of PET today.
83
 Amongst other techniques in nuclear medicine, PET became 
an important tool of modern molecular imaging. Thus three - dimensional graphical 
representation of regional and timely distribution of radiopharmaceuticals in the human body 
became possible. In the future, positron emission tomography will especially focus on brain 
research and still on cancer. Faster reacting detector crystals with higher density and more 
light output are in development in order to achieve better results. Hence the use of PET-CT-
scanner combination gains popularity due to the advantage of combining the functional data 
of a PET scan with the anatomical accuracy of a CT scan.
71
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2 RESULTS AND DISCUSSION 
 
2.1 Aim  
 
The adenosine A3 receptor subtype (A3AR) is involved in a variety of pathologies, especially 
neurological and psychiatric diseases (cerebral ischemia, glaucoma, stroke, and epilepsy). 
Thus, Wadsak et al recently reported on the preparation and evaluation of [
18
F]FE@SUPPY 
(2-Fluorethyl-4,5-diethyl-5-[(ethylsulfanyl)carbonyl]-2-phenylpyridin-3-carboxylat),
84
 the 
first PET radiotracer for the adenosine A3 receptor and on SUPPY:0 (4,6-diethyl-2-phenyl-5-
(sulfanylcarbonyl)pyridine-3-carboxylic acid)
85
 a versatile precursor for a variety of 
metabolites and derivatives of SUPPY-type PET radiotracers. 
Hence, the aim of this thesis was the preparation of several SUPPY:0 derivatives. One new 
compound (6) has been developed and nine new synthetic pathways for already known 
derivatives (1-3, 5, 7) were established.  
 
 
 
With a few exceptions microwave-assisted synthetic techniques were used, which allowed the 
synthesis of each target compound in one to two steps starting from SUPPY:0 (scheme 1). 
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SUPPY:0 was alkylated with different alkyl halides and alkyl triflates under microwave 
conditions yielding in most cases O/S - regioselective products. 
In conclusion, a straightforward synthetic method was established to compounds required as 
precursors for radiolabeling and as reference compounds for HPLC analysis of labeled 
SUPPY-type PET tracers. 
 
2.2 Reaction schemes: 
 
Scheme 1: 
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2.3 Syntheses 
 
2.3.1 Preparation of 4,6-diethyl-2-phenyl-5-thiocarboxy-pyridine-3-carboxylic acid,  
 SUPPY:0 (4) 
 
This compound was prepared according to Shanab
2
 deviating in a few synthetic 
improvements, regarding reaction solvents and the eluting mixtures for purification, to 
increase yields (scheme 2). 
Furthermore, 4,6-diethyl-2-phenyl-5-thiocarboxy-pyridine-3-carboxylic acid (SUPPY:0) (4) 
was used as starting material for four compounds (1-3, 5). While mono-substituted products 
(1-3, 5) can serve as precursor for further radiosynthetic experiments, bis-substituted 
compounds (6, 7) serve as references for HPLC analyses. 
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Scheme 2: 
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2.3.1.1 4-Methoxybenzyl 3-oxo-3-phenylpropanoate (9) 
 
In order to obtain the pyridine derivative SUPPY:0, the preparation of β-ketoester (9) was 
required. This procedure was carried out in two reaction steps (scheme 3). 
 
 
Scheme 3 
 
For the first reaction step 2,2-dimethyl-1,3-dioxane-4,6-dione was reacted with benzoyl 
chloride and pyridine in absolute dichloromethane under argon atmosphere. By acylation of 
meldrum’s acid, 5-benzoyl-2,2-dimethyl-1,3-dioxane-4,6-dione (8) was prepared in good 
yields. 
The second reaction step was necessary to afford β-ketoester (9) by treatment p-
methoxybenzyl alcohol in toluene. Ring opening occurred under decarboxylation to give 
compound 3. The crude product was purified several times by column chromatography using 
a mixture of petrolether and ethyl acetate as eluent. Compared to Shanab
2
, who used 
petrolether/ethyl acetate 1:1, the ratio of petrolether to ethyl acetate was 8:2, which led to 
improved separation. 
 
2.3.1.2 4-Methoxybenzyl 3-amino-3-phenylacrylate (10) 
 
 
Scheme 4 
 
The required enamine (10) was obtained by adding ammoniumacetate to a mixture of 4-
methoxybenzyl 3-oxo-3-phenylpropanoate (9) and tetraethyl orthosiliate in absolute ethanol. 
This mixture was stirred for 48 h under argon atmosphere to afford the product (10) in 
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excellent yields (scheme 4). The completion of the reaction was monitored by thin layer 
chromatography. After removal of the solvent under reduced pressure the brownish oily 
residue was purified by column chromatography. 
 
2.3.1.3 3-Allyl 5-(4-methoxybenzyl)-2,4-diethyl-6-phenyl-1,4-dihydropyridine-3,5  
 dicarboxylate (13) 
 
The product obtained from the previous reaction step (10) was subjected to the following 
reaction to give the desired 1,4-dihydropyridine (13) (scheme 5). 
 
 
Scheme 5 
 
Enamine (10), the β-ketoester (11) and propionaldehyde (12) were heated in an ethanolic 
solution in an autoclave at 80°C for 24 h to form the desired product (13) in a Hantzsch 
condensation. The following thin layer chromatography showed typical fluorescence of the 
product (13) at 366 nm. Column chromatography afforded the pure final product as yellow-
greenish oil.  
 
2.3.1.4 3-Allyl 5-(4-methoxybenzyl)-2,4-diethyl-6-phenylpyridine-3,5-dicarboxylate (14) 
 
Scheme 6 
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Oxidation of dihydropyridine (13) to pyridine (14) was carried out with 2,3,5,6-
tetrachlorobenzo-1,4-quinone in tetrahydrofuran (scheme 6). The mixture was heated to reflux 
overnight to assure completion of the reaction which was detected by thin layer 
chromatography. In comparison to the starting material the product (14) did not show 
fluorescence at 366 nm. The crude product was purified by column chromatography to give a 
colorless-reddish oil. 
 
2.3.1.5 2,4-Diethyl-5-[(4-methoxybenzyloxy)carbonyl]-6-phenylpyridine-3-carboxylic  
 acid (15) 
 
The subsequent step allowed selective cleavage of the allyl protecting group by using a 
tetrakis(triphenylphosphine)palladium catalyst and morpholine as nucleophile (scheme 7).  
Resonance stabilization of the carboxylate anion activates the allyl ester for nucleophilic 
attack by the palladium catalyst, which results in the formation of a π-allyl-palladium 
complex. The nucleophile (e.g. morpholine, pyrrolidine, or dimedone) traps this very complex 
to liberate the carboxylic acid.  
 
Scheme 7 
 
The reaction was carried out under argon atmosphere. Carboxylic acid (15) was obtained by 
treating the allyl ester (14) with the reagents depicted in scheme 7. The obtained product 
required extensive purification. The catalyst was removed by suction and the crude product 
was purified by silica gel column chromatography. Due to remaining impurities purification 
was repeated several times until the product (15) was obtained as light orange crystals. 
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2.3.1.6 4-Methoxybenzyl 5-(chlorocarbonyl)-4,6-diethyl-2-phenylpyridine-3-carboxylate  
 (16) 
 
The next step consisted of the conversion of the carboxylic acid (15) into a thiocarboxylic 
acid via acid chloride (16) by treatment with oxalylchloride and dimethylformamide as 
catalyst in benzene (scheme 8). 
 
Scheme 8 
 
In order to increase yields, reaction mixture was cooled to a temperature of 0°C during 
addition of the reagents. Then the solution was stirred at room temperature for 2 hours. After 
the reaction had reached completion, the solvent was removed under reduced pressure and to 
remove residues of benzene the crude product was co-evaporated several times with toluene. 
Acid chloride (16) was directly used for the next reaction step (2.3.1.7) without further 
purification. 
 
2.3.1.7 2,4-Diethyl-5-[(4-methoxybenzyloxy)carbonyl]-6-phenylpyridine-3-carbothioic S- 
 acid (17) 
 
In order to maximize yields 4-methoxybenzyl 5-(chlorocarbonyl)-4,6-diethyl-2-
phenylpyridine-3-carboxylate (16) was dried under vacuum prior to the subsequent reaction 
(scheme 9). 
 
Scheme 9 
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Before the addition of the reagents the reaction mixture was cooled to -10°C. Sodium 
hydrosulfide serves as SH
-
 ion donor which is substituting the chlorine atom by nucleophilic 
attack following a SN2t mechanism.  
Cooling was stopped to allow warming of the reaction mixture to room temperature. Stirring 
was continued for one additional hour to obtain 17 in moderate yields. The purification of 
thiocarboxylic acid (17) was rather tedious due to formation of by-products. At this point of 
the synthesis reversed phase chromatography was utilized for purification to separate by-
products efficiently. Purification was repeated several times to meet purity requirements for 
NMR spectroscopy. 
 
2.3.1.8 4,6-Diethyl-2-phenyl-5-(sulfanylcarbonyl)pyridine-3-carboxylic acid (4) 
 
The final step of the SUPPY:0 synthesis required cleavage of the p-methoxybenzyl protecting 
group  
 
 
Scheme 10 
 
The cleavage was performed by treating (17) with formic acid at room temperature (scheme 
10). After stirring for 3 hours, the formic acid was evaporated. The crude product was purified 
by reversed phase column chromatography (acetonitrile/water) several times to give the crude 
product as white crystals in moderate yield. 
 
 
 
 
 
 
 
 
 30 
2.3.2 Preparation of 2,4-diethyl-5-(methoxycarbonyl)-6-phenylpyridine-3-carbothioic 
 S-acid (1) 
 
Preparation of product 1 was realized in two different pathways: 
 
2.3.2.1 Microwave assisted synthesis 
 
 
Scheme 11 
 
For this pathway, the starting material, SUPPY:0 (4), was treated with methyl 
trifluoromethanesulfonate and caesium carbonate (scheme 11), which served as an ionic 
additive to improve the microwave absorbtion of the solvent on the one hand and as a base on 
the other hand. Acting as a base, caesium carbonate was used to deprotonize carboxylic acid 4 
to activate it for the nucleophilic attack of methyl trifluoromethanesulfonate. This reaction 
afforded white crystals in moderate yields. 
 
2.3.2.2 Preparation with diazomethane 
 
The second pathway was carried out with diazomethane (scheme 12). In comparison to the 
microwave assisted approach, this method provided better yields.  
 
 
Scheme 12 
 
For the preparation of 2,4-diethyl-5-(methoxycarbonyl)-6-phenylpyridine-3-carbothioic S-
acid (1), SUPPY:0 was treated with trimethylsilyl diazomethane in a mixture of toluene and 
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methanol as solvent. This solution was stirred at room temperature for 30 min. Finally, white 
crystals were obtained in good yield. 
 
2.3.3 Preparation of 5-(ethoxycarbonyl)-2,4-diethyl-6-phenylpyridine-3-carbothioic S- 
 acid (2) 
 
 
Scheme 13 
 
The synthesis of derivative 2 was achieved by treating SUPPY:0 (4) with the appropriate 
triflate under microwave conditions which allow rapid heating of the reactants up to 150 °C in 
low boiling solvents (acetonitrile) (scheme 13). Cesium ions (caesium carbonate) were added 
to improve the absorption and conversion of the microwave energy into heat by an ionic 
conduction mechanism. Under the investigated conditions the alkylation always occurred on 
the carboxylic acid and not on the thiocarboxylic moiety. Compound 2 was obtained in good 
yield prior to several purification steps. 
 
2.3.4 Preparation of 2,4-diethyl-5-[(2-fluoroethoxy)carbonyl]-6-phenylpyridine-3-  
 carbothioic S-acid (3) 
 
For the synthesis of compound 3 2-fluoroethyl trifluoromethanesulfonate was prepared 
following a procedure of Chi et al.
86
 In a microwave assisted synthesis 2,4-diethyl-5-[(2-
fluoroethoxy)carbonyl]-6-phenylpyridine-3-carbothioic S-acid (3) was obtained by treating 
the starting material (4) with the depicted reagent (scheme 14). 
 
 
Scheme 14 
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Preparing compound 3 under microwave conditions had the advantage of the reaction mixture 
heating up quickly to 150°C in low boiling solvents, such as acetonitrile. Consequently, the 
use of high boiling solvents such as dimethylformamide and dimethyl sulfoxide could be 
avoided, which are usually difficult to remove. 
As mentioned above (2.3.2 and 2.3.3), cesium ions were added to improve the absorption and 
the conversion of microwave energy into heat. 
 
2.3.5 Preparation of 4,6-diethyl-5-(methylthiocarbonyl)-2-phenylpyridine-3-carboxylic  
 acid (5) 
 
Product 5 was synthesized using the conventional heating method with SUPPY:0 (4) as 
starting material (scheme 15). 
 
 
Scheme 15 
 
After addition of methyl trifluoromethanesulfonate and heating to 150°C the solution turned 
yellow. Thin layer chromatography and a reversed phase thin layer chromatography were 
performed to monitor the progress of the reaction. The latter showed that the addition of more 
methyl trifluoromethanesulfonate was required. After stirring another 15-20 min the solvent 
was removed by Kugelrohr distillation. 
Due to formation of many by-products compound 5 was purified several times. The utilization 
of reversed phase column chromatography was necessary to eliminate very non-polar 
impurties and silica gel 60 column chromatography was necessary for the final purification of 
compound 5.  
The purity of product 5 was increased by additional extraction with ethyl acetate following 
column chromatography. 
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The addition of sodium thiosulfate a solution reduced elemental iodine and decolorized the 
crude product but also resulted in a decreased yield. 
 
2.3.6 Preparation of 2-fluoroethyl-4,6-diethyl-5-(methylthiocarbonyl)-2-phenylpyridine- 
 3-carboxylic acid (6) 
 
For this microwave assisted synthesis, 4,6-diethyl-5-(methylthiocarbonyl)-2-phenylpyridine-
3-carboxylic acid (5) was used as starting material. 
 
 
Scheme 16 
 
Compound 5 was treated with 2-fluoroethyl trifluoromethanesulfonate and cesium ions as 
cesium carbonate in acetonitrile to give product 6 in moderate yield (scheme 16). Thin layer 
chromatography showed the consumption of the starting material and a significant amount of 
the assumed product (6). Compound 6 was purified several times by column chromatography 
to be finally isolated as colorless oil. 
 
2.3.7 Preparation of methyl 4,6-diethyl-5-(methylthiocarbonyl)-2-phenylpyridine-3- 
 carboxylic acid (7) 
 
The synthesis of product 7 was attempted by 3 different methods: 
 
1. Methylation with methyl trifluoromethanesulfonate 
2. Methylation with methyl iodide and sodium hydride 
3. Methylation with diazomethane  
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2.3.7.1 Methylation of 2,4-diethyl-5-(methoxycarbonyl)-6-phenylpyridine-3-carbothioic  
 S-acid (1) with methyl trifluoromethanesulfonate 
 
This reaction was carried out by treating starting material 1 with sodium iodide and methyl 
trifluoromethanesulfonate in dimethylformamide (scheme 17). 
 
 
Scheme 17 
 
Thin layer chromatography was carried out after completion of the reaction time, but no 
product could be detected. Even addition of excess methyl trifluoromethanesulfonate and 
prolonged reaction times did not afford the desired product. 
 
2.3.7.2 Methylation of 2,4-diethyl-5-(methoxycarbonyl)-6-phenylpyridine-3-carbothioic 
 S-acid (1) via methyl iodide and sodium hydride 
 
For this reaction, compound 1 served also as starting material. 
 
 
Scheme 18 
 
The reaction was carried out with sodium hydride in tetrahydrofurane and methyl iodide 
(scheme 18). The mixture was stirred at 0°C and every 30 min. thin layer chromatography 
was performed. Since no conversion was detected, the solution was stirred at room 
temperature for 72 h. The crude product was purified by column chromatography, but only 
minimal amounts of a product were obtained.  
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NMR spectra were recorded which revealed the loss of the sulfur atom indicated by the shift 
of the signal at about 190.0 ppm (thiocarboxyl carbon) to about 170.0 ppm (carboxyl carbon). 
Thus, it was concluded that product 18 had formed instead of desired compound 7. 
 
 
 
2.3.7.3 Methylation of 4,6-diethyl-5-(methylthiocarbonyl)-2-phenylpyridine-3-carboxylic  
 acid (5) with diazomethane 
 
This reaction was carried out using conventional heating with compound 5 as starting 
material, which led successfully to product 7 (scheme 19). 
 
 
Scheme 19 
 
The reaction was carried out under argon atmosphere. An excess amount of diazomethane in 
hexane was added since thin layer chromatography showed only low conversion with with 
equimolar amounts. Subsequently, the crude product was purified by column chromatography 
to afford compound 7 as light yellow crystals.  
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3 EXPERIMENTAL 
 
3.1 General 
 
Recording of spectra: 
Infrared spectra: Perkin-Elmer FTIR spectrometer Spectrum 1000 (KBr pellets).  
1
H, 
13
C NMR Spectra: Bruker Avance DPX-200 spectrometer at 27°C (200.13 MHz for 
1
H, 
50.32 MHz for 
13
C). The solvent signal is used as internal reference standard related to TMS, 
occurring at δ = 7.26 ppm (1H in CDCl3), δ = 2.49 ppm (
1
H in DMSO-d6), δ = 77.0 ppm (
13
C 
in CDCl3) and δ = 39.5 ppm (
13
C in DMSO-d6).  
Mass spectra: Shimadzu QP 1000 (EI, 70 eV), direct inlet 
High resolution mass spectra: Finnigan MAT 8230 (EI, 70 eV) and Finnigan MAT 900 S 
(ESI, 4 kV, 3 μA CH3CN/MeOH). 
 
Chromatographic separation: 
Thin layer chromatography: Merck TLC Silica Gel 60 F254 aluminum sheets, layer 
thickness 0.2 mm; Merck TLC Silica Gel 60 RP-18 F254s aluminum sheets, layer thickness 
0.2 mm. 
Column chromatography: Merck Silica Gel 60 F254; Merck Silica Gel 60 RP-18 F254s 
 
Other: 
Microwave: Synthos 3000 microwave oven with a SXQ80 rotor of Anton Paar 
Melting points: Reichert-Kofler hot-stage microscope 
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3.2 Syntheses 
 
3.2.1 Preparation of 4,6-diethyl-2-phenyl-5-thiocarboxy-pyridine-3-carboxylic acid (4) 
 
3.2.1.1 4-Methoxybenzyl 3-oxo-3-phenylpropanoate (9) 
 
 
 
2,2-Dimethyl-1,3-dioxane-4,6-dione (40.00 g, 227.53 mmol) and benzoyl chloride (35.5 ml, 
0.28 mmol) were dissolved in dichloromethane (400 ml) and stirred under argon atmosphere. 
The solution was cooled to -40°C and pyridine was added. After reaching 0°C the reaction 
mixture was stirred for 1 hour and one additional hour after reaching room temperature.  
The reaction mixture was then extracted with 1N HCl (200 ml) and water (115 ml) and dried 
over Na2SO4. The solvent was removed under reduced pressure and the residue was directly 
used for the next step, without further purification. 
The crude product and 4-methoxybenzylalcohol (115 g, 832.37 mmol) was dissolved in 
toluene and stirred for 24 h at 80°C. After removal of the solvent, the oily product 9 was 
purified by column chromatography (silica gel 60, petrolether/EtOAc 8+2). 
 
Yield: 43.02 g (67%) reddish oil  
 
Spectroscopic data were in complete accordance with literature values.
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 38 
3.2.1.2 4-Methoxybenzyl 3-amino-3-phenylacrylate (10) 
 
 
 
To a solution of 4-methoxybenzyl 3-oxo-3-phenylpropanoate (42.00 g, 148.24 mmol) and 
tetraethyl orthosilicate (61.77 g, 229.50 mmol) dissolved in absolute ethanol (600 ml), 
ammoniumacetate (57.13 g, 741.18 mmol) was added. The resulting solution was heated to 
reflux and argon atmosphere for 48 hours. Thereafter the solvent was removed under reduced 
pressure and product 10 was purified by column chromatography (silica gel 60, 
petrolether/EtOAc 8+2). 
 
Yield: 38.02 g (91 %) brownish oil 
 
Spectroscopic data were in complete accordance with literature values.
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 39 
3.2.1.3 3-Allyl 5-(4-methoxybenzyl)-2,4-diethyl-6-phenyl-1,4-dihydropyridine-3,5- 
 dicarboxylate (13) 
 
 
4-Methoxybenzyl 3-amino-3-phenylacrylate (43.02 g, 151.84 mmol), propionaldehyde (8.82 
g, 151.84 mmol) and allyl-3-oxopentanoate (23.71 g, 151.84 mmol) were dissolved in 
absolute ethanol and stirred in an autoclave for 24h at 80°C. After cooling to room 
temperature, the solvent was removed and the residue was purified by column 
chromatography (silica gel 60, petrolether/EtOAc 8+2). 
 
Yield: 36.54 g (52%) yellow-greenish oil 
 
Spectroscopic data were in complete accordance with literature values.
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 40 
3.2.1.4 3-Allyl 5-(4-methoxybenzyl)-2,4-diethyl-6-phenylpyridine-3,5-dicarboxylate (14) 
 
 
 
3-Allyl 5-(4-methoxybenzyl)-2,4-diethyl-6-phenyl-1,4-dihydropyridine-3,5-dicarboxylate 
(36.54 g, 79.27 mmol) and 2,3,5,6-tetrachloro-1,4-benzoquinone (21.44 g, 87.23 mmol) in 
THF (600 ml) were heated to reflux overnight. The reaction mixture was cooled to room 
temperature and the solvent evaporated prior to the purification by column chromatography 
(silica gel 60, petrolether/EtOAc 9+1). 
 
Yield: 34.03 g (94%) red-brownish oil 
 
Spectroscopic data were in complete accordance with literature values.
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 41 
3.2.1.5 2,4-Diethyl-5-[(4-methoxybenzyloxy)carbonyl]-6-phenylpyridine-3-carboxylic 
 acid (15) 
 
 
 
Tetrakis(triphenylphosphine)palladium (9.16 g, 7,93 mmol) and morpholine (82.7 ml, 950.81 
mmol) were added to a stirred solution of 3-allyl 5-(4-methoxybenzyl)-2,4-diethyl-6-
phenylpyridine-3,5-dicarboxylate (56.03 g, 146.11 mmol) in THF (588 ml) under argon 
atmosphere at room temperature. The mixture was cooled and stirred for 30 min. After 
removal of the solvent under reduced pressure at room temperature, ethyl acetate (300 ml) 
was added until the residue was dissolved. The solution was then extracted three times with 
1N HCl and the catalyst removed by suction. After drying over Na2SO4, the solvent was 
removed under reduced pressure and product 15 was purified by column chromatography 
(silica gel 60, EtOAc/MeOH 8+2). 
 
Yield: 48.92 g (96 %) light orange crystals, mp. 137-139° C 
 
Spectroscopic data were in complete accordance with literature values.
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 42 
3.2.1.6 4-Methoxybenzyl 5-(chlorocarbonyl)-4,6-diethyl-2phenylpyridine-3-carboxylate  
 (16) 
 
 
 
To a solution of 2,4-diethyl-5-[(4-methoxybenzyloxy)carbonyl]-6-phenylpyridine-3-
carboxylic acid (16.92 g, 40.34 mmol) in benzene (170 ml), oxalyl chloride (17 ml, 0.20 
mmol) and DMF (1 ml) were added dropwise at -10°C. After reaching room temperature, the 
solution was stirred for 2h. Then the solvent was removed under reduced pressure and the oily 
product was co-evaporated with toluene several times. The resulting product 16 was used 
immediately for the next reaction step (3.2.1.7) without further purification.  
 
 
 
 
 
 
 
 
 
 
 
 
 43 
3.2.1.7 2,4-Diethyl-5-[(4-methoxybenzyloxy)carbonyl]-6-phenylpyridine-3-carbothioic-S  
 acid (17) 
 
 
 
The product (16) of the previous reaction step was dissolved in THF (10 ml) and added 
dropwise to a solution of NaHS hydrate (2.26 g, 40.31 mmol) in absolute ethanol (100 ml) at  
-10°C. After reaching room temperature, the mixture was stirred for one hour and then 
acidified with 2N HCl. The aqueous layer was extracted with EtOAc. The organic layer was 
washed twice with a saturated NaCl solution and dried over Na2SO4. Then the solvent was 
removed under reduced pressure and the crude product 17 was purified by reversed - phase 
column chromatography (RP-18 silica gel, CH3CN/H2O 8+2) 
 
Yield: 8.14 g (46%) colorless crystals, mp. 59-60° C 
 
Spectroscopic data were in complete accordance with literature values.
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 44 
3.2.1.8 4,6-Diethyl-2-phenyl-5-(sulfanylcarbonyl)pyridine-3-carboxylic acid (4) 
 
 
 
Formic acid (80 ml) was added to 2,4-diethyl-5-[(4-methoxybenzyloxy)carbonyl]-6-
phenylpyridine-3-carbothioic-S-acid (8 g, 18.37 mmol) and stirred at room temperature for 3 
hours. Then formic acid was removed under reduced pressure and the product 4 was purified 
by reversed phase column chromatography (RP-18 silica gel, CH3CN/H2O 9.5+0.5). 
 
Yield: 2.41 g (42%) colorless crystals, mp. 191° C 
 
Spectroscopic data were in complete accordance with literature values.
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 45 
3.2.2 Preparation of 2,4-diethyl-5-(methoxycarbonyl)-6-phenylpyridine-3-carbothioic       
 S-acid (1) 
 
3.2.2.1 Microwave assisted synthesis 
 
 
 
4,6-Diethyl-2-phenyl-5-(sulfanylcarbonyl)pyridine-3-carboxylic acid (0.10 g, 0.33 mmol), 
Cs2CO3 (0.22 g, 0.66 mmol) and methyl trifluoromethanesulfonate (0.11g, 0.69 mmol) were 
suspended in CH3CN (10 ml). The reaction mixture was heated in a microwave oven to 150°C 
at 300 W for 15 min. Then the solvent was removed under reduced pressure and the product 
purified by column chromatography (silica gel 60, CH3CN). 
 
Yield: 30 mg (29%) white crystals, mp. 161-162° C 
 
Spectroscopic data were in complete accordance with literature values.
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 46 
3.2.2.2 Preparation with diazomethane 
 
 
 
To a stirred solution of 4,6-diethyl-2-phenyl-5-(sulfanylcarbonyl)pyridine-3-carboxylic acid 
(0.20 g, 0.63 mmol) in toluene/MeOH (9+6), trimethylsilyldiazomethane(0.4 ml, 0.63 mmol) 
was added dropwise until the yellow color of the mixture persisted. Thereafter, the solution 
was stirred for another 30 min at room temperature. The solvent was removed by reduced 
pressure and the product 1 purified by reversed phase column chromatography (RP-18 silica 
gel, CH3CN/H2O 9+1). 
 
Yield: 141 mg (68%) white crystals, mp. 161-162° C 
 
Spectroscopic data were in complete accordance with literature values.
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 47 
3.2.3 Preparation of 5-(ethoxycarbonyl)-2,4-diethyl-6-phenylpyridine-3-carbothioic S- 
 acid (2) 
 
 
 
To a solution of 4,6-diethyl-2-phenyl-5-(sulfanylcarbonyl)pyridine-3-carboxylic acid (0.22 g, 
0.70 mmol) and Cs2CO3 (0.42 g, 1.29 mmol) in CH3CN (15 ml), ethyl 
trifluoromethanesulfonate (0.42 g, 2.36 mmol) was added. The mixture was heated in the 
microwave oven to 150°C at 300 W for 10 min. Then the solvent was evaporated and crude 
product 2 purified by reversed phase column chromatography (RP-18 silica gel, CH3CN/H2O 
9+1). 
 
Yield: 120 mg (50%) yellow oil 
 
Spectroscopic data were in complete accordance with literature values.
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 48 
3.2.4 Preparation of 2,4-diethyl-5-[(2-fluoroethoxy)carbonyl]-6- phenylpyridine-3- 
 carbothioic S-acid (3) 
 
3.2.4.1 2-Fluoroethyl trifluoromethanesulfonate 
 
 
 
To a solution of 2-fluoroethanol (10.0 g, 156.10 mmol) in lutidine (20 ml) CH2Cl2 (100 ml) 
was added after cooling the mixture below 0°C. After adding trifluoromethanesulfonic 
anhydride (55 ml, 327.81 mmol) dropwise, the solution was stirred for 30 min at 0°C. Finally, 
a mixture of 10% EtOAc in hexane (50 ml) was added. For purification, the solution was 
passed through a silica gel cartridge. After removal of the solvent the product (3) was purified 
by Kugelrohr distillation. 
 
Yield: 29.08 g (95%) colorless fluid 
 
Spectroscopic data were in complete accordance with literature values.
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 49 
3.2.4.2 2,4-Diethyl-5-[(2-fluoroethoxy)carbonyl]-6-phenylpyridine-3-carbothioic S-acid  
 (3) 
 
 
 
4,6-Diethyl-2-phenyl-5-(sulfanylcarbonyl)pyridine-3-carboxylic acid (0.25 g, 0.79 mmol), 
Cs2CO3 (0.52 g, 1.59 mmol) and 2-fluoroethyl trifluoromethanesulfonate (0.34 g, 1.74 mmol) 
were suspended in CH3CN (45 ml). The reaction mixture was heated in a microwave oven at 
350 W to 150°C for 20 min. Thereafter, the solvent was evaporated and the resulting product 
3 purified by column chromatography (silica gel 60, petrolether/EtOAc 9+1). 
 
Yield: 87 mg (30%) light brown oil 
 
Spectroscopic data were in complete accordance with literature values.
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 50 
3.2.5 Preparation of 4,6-diethyl-5-(methylthiocarbonyl)-2-phenylpyridine-3-carboxylic  
 acid (5) 
 
 
 
4,6-Diethyl-2-phenyl-5-(sulfanylcarbonyl)pyridine-3-carboxylic acid (0.10 g, 0.32 mmol) and 
NaI (0.48 g, 3.17 mmol) were dissolved in DMF (10 ml) to stir the solution at room 
temperature. Then the reaction mixture was heated to 155°C and methyl 
trifluoromethanesulfonate (0.12 g, 0.71 mmol) was added. The solution was stirred for 
another 15-20 min. Thereafter, DMF was removed by Kugelrohr distillation and the product 5 
was purified by column chromatography (silica gel 60, petrolether/EtOAc 8+2). The orange-
red solution was alkalized with NaOH and extracted with EtOAc. The aqueous layer was 
acidified with 2N HCl and extracted again with EtOAc. Finally, the combined organic layers 
were dried over Na2SO4 and the solvent removed under reduced pressure. 
 
Yield: 52 mg (49%) white crystals, mp. 243-244° C 
 
Spectroscopic data were in complete accordance with literature values.
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 51 
3.2.6 Preparation of 2-fluoroethyl 4,6-diethyl-5-(methylthiocarbonyl)-2-phenylpyridine- 
 3-carboxylic acid (6) 
 
 
 
To a solution of 4,6-diethyl-5-(methylthiocarbonyl)-2-phenylpyridine-3-carboxylic acid   
(0.05 g, 0.15 mmol) and Cs2CO3 (0.99 g, 0.30 mmol) in CH3CN (15 ml), 2-fluoroethyl 
trifluoromethanesulfonate (0.63 g, 0.33 mmol) was added. The reaction mixture was heated in 
a microwave oven at 350 W to 150°C for 20 min. Then the solvent was removed under 
reduced pressure and the crude product 5 purified by column chromatography (silica gel 60, 
petrolether/EtOAc 8+2). 
 
Yield: 18 mg (32%) colorless oil 
 
1
H-NMR (200 MHz, CDCl3): δ (ppm) 7.59 (m, 2H), 7.43 (m, 3H), 4.42 (m, 1H), 4.33 (m, 
1H), 4.31 (q, J = 7.5 Hz, 2H), 4.19 (s, 2H), 2.72 (q, J = 7.6 Hz, 2H), 2.56 (s, 3H), 1.33 (t, J = 
7.4 Hz, 3H), 1.23 (t, J = 7.6 Hz, 3H) 
 
13
C-NMR (50 MHz, CDCl3): δ (ppm) 195.6, 168.2, 159.8, 157.3, 148.2, 139.8, 133.1, 128.9, 
128.4, 128.3, 125.9, 82.2, 78.8, 64.3, 63.9, 29.2, 24.2, 15.7, 14.1, 12.7 
 
IR (KBr): ν (cm-1) 3664, 2932, 2926, 2852, 1732, 1668, 1556, 1496, 1460, 1406, 1376, 1266, 
1252 
 
MS: m/z (%) 375.25 (M
+
 + H, 1), 330.40 (2), 329.35 (21), 328.25 (100), 282.10 (6), 254.10 
(5), 236.15 (5), 208.20 (3) 
 
HRMS: m/z calculated for C20H22FNSO3H: 376.1383. Found: 367.1385 
 52 
3.2.1 Preparation of methyl 4,6-diethyl-5-(methylthiocarbonyl)-2-phenylpyridine-3- 
 carboxylic acid (7) 
 
3.2.7.1 Preparation via diazomethane 
 
 
 
To a stirred solution of 4,6-diethyl-5-(methylthiocarbonyl)-2-phenylpyridine-3-carboxylic 
acid (0.08 g, 0.26 mmol) in toluene/MeOH (10 ml, 6+4) under argon atmosphere, 
trimethylsilyldiazomethane (0.44 g, 0.38 mmol) was added and stirred for 30 min. After 
evaporation of the solvent, the crude product (7) was purified by column chromatography 
(silica gel 60, petrolether/EtOAc 8+2) 
 
Yield: 57 mg (64%) light yellow crystals, mp. 77°C 
 
Spectroscopic data were in complete accordance with literature values.
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 53 
3.2.7.2 Preparation of dimethyl 2,4-diethyl-6-phenylpyridine-3,5-dicarboxylate (18) 
 
 
 
A 60% NaH dispersion in mineral oil (0.01 g, 0.23 mmol) was washed with hexane (3 ml) 
which was then replaced by THF (5 ml) prior to the slow addition of a solution of 2,4-diethyl-
5-(methoxycarbonyl)-6-phenylpyridine-3-carbothioic S-acid (0.07 g, 0.21 mmol) in THF (2 
ml). Thereafter, the mixture was cooled to 0°C and MeI (0.04 g, 0.25 mmol) was added 
carefully.  
After two hours, thin layer chromatography (silica gel 60, petrolether/EtOAc 9+1) was carried 
out, but no product could be detected. Thus, the mixture was stirred for another 48 hours. 
After completion of the reaction, the solvent was evaporated and the crude product (18) 
purified by column chromatography (silica gel 60, petrolether/EtOAc 8+2). 
 
Yield: 30 mg (43%) violet-reddish oil 
 
1
H-NMR (200 MHz, CDCl3): δ (ppm) 7.60 (m, 2H), 7.42 (m, 3H), 3.96 (s, 3H), 3.62 (s, 3H), 
2.83 (q, J = 7.5 Hz, 2H), 2.66 (q, J = 7.6 Hz, 2H), 1.32 (t, J = 7.4, 3H), 1.22 (t, J = 7.6, 3H) 
 
13
C-NMR (50 MHz, CDCl3): δ (ppm) 169.1, 169.0, 160.3, 156.7, 148.6, 139.7, 128.8, 128.4, 
128.2, 127.3, 126.2, 52.4, 52.3, 29.8, 24.9, 15.2, 13.7 
IR (KBr): ν (cm-1) 3446, 2974, 2948, 2878, 2854, 1730, 1562, 1496, 1448, 1436, 1410, 1376, 
1308, 1268, 1252 
 
MS: m/z (%) 328.30 (M
+
 + H, 15), 312.25 (100), 296.25 (27), 280.25 (22), 254.10 (15), 
236.00 (11), 207.95 (14) 
 
HRMS: m/z calculated for C19H21NO4H: 328.1549. Found: 328.1554 
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 5 APPENDIX 
 
5.1 Spectra 
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